{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T03:22:50Z","timestamp":1761016970069},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[1996,11]]},"abstract":"<jats:p>\n            <jats:italic>Background<\/jats:italic>\n            Coxsackieviruses B (CBVs) are dominant causative agents in myocarditis and are associated with pathogenesis in some cases of dilated cardiomyopathy, a clinical entity with a poor survival without heart transplantation.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Methods and Results<\/jats:italic>\n            In vitro, the antiviral agent WIN 54 954 was shown to inhibit replication of CBV3 at a minimal inhibitory concentration value of 0.02 mg\/L. Administration of WIN 54 954, 100 mg\/kg BID PO, beginning on the day of infection resulted in complete protection from enteroviral mortality (\n            <jats:italic>P<\/jats:italic>\n            &lt;.01). WIN 54 954 treatment did not abrogate the inflammatory reaction in the myocardium. No difference was found in the expression of surface lymphocyte subset markers. At 3 weeks, macrophages seemed to dominate the inflammatory reaction, regardless of treatment. There was no difference in CBV3 antibody titers, indicating that WIN 54 954 does not interfere with the development of protective immunity. Complement factors C3 and B were synthesized at a higher level during infection and correlated well with the degree of inflammatory reaction.\n          <\/jats:p>\n          <jats:p>\n            <jats:italic>Conclusions<\/jats:italic>\n            The results show that WIN 54 954 is a potent antiviral agent with a highly significant effect on survival in CBV-induced myocarditis in the A\/J mouse if treatment is started early. It is suggested that the reduction in mortality seen with WIN 54 954 administration is due to an inhibitory effect on virus replication in affected organs that does not interfere with cellular or humoral immunity.\n          <\/jats:p>","DOI":"10.1161\/01.cir.94.9.2254","type":"journal-article","created":{"date-parts":[[2012,6,12]],"date-time":"2012-06-12T00:34:42Z","timestamp":1339461282000},"page":"2254-2259","update-policy":"http:\/\/dx.doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":23,"title":["Antiviral Treatment With WIN 54 954 Reduces Mortality in Murine Coxsackievirus B3 Myocarditis"],"prefix":"10.1161","volume":"94","author":[{"given":"J.","family":"Fohlman","sequence":"first","affiliation":[{"name":"the Department of Infectious Diseases, University Hospital, Uppsala, Sweden (J.F., K.P., N.G.I., G.F.); the Department of Virology, University of Turku, Finland (T.H.); Toxicology and Safety Assessment, Kabi Pharmacia AB, Helsingborg, Sweden (N.G.I.); the Division of Clinical Virology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden (A.E.); and the Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Huddinge Hospital, Huddinge, Sweden (G.E.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Pauksen","sequence":"additional","affiliation":[{"name":"the Department of Infectious Diseases, University Hospital, Uppsala, Sweden (J.F., K.P., N.G.I., G.F.); the Department of Virology, University of Turku, Finland (T.H.); Toxicology and Safety Assessment, Kabi Pharmacia AB, Helsingborg, Sweden (N.G.I.); the Division of Clinical Virology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden (A.E.); and the Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Huddinge Hospital, Huddinge, Sweden (G.E.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Hyypia\u00a8","sequence":"additional","affiliation":[{"name":"the Department of Infectious Diseases, University Hospital, Uppsala, Sweden (J.F., K.P., N.G.I., G.F.); the Department of Virology, University of Turku, Finland (T.H.); Toxicology and Safety Assessment, Kabi Pharmacia AB, Helsingborg, Sweden (N.G.I.); the Division of Clinical Virology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden (A.E.); and the Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Huddinge Hospital, Huddinge, Sweden (G.E.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Eggertsen","sequence":"additional","affiliation":[{"name":"the Department of Infectious Diseases, University Hospital, Uppsala, Sweden (J.F., K.P., N.G.I., G.F.); the Department of Virology, University of Turku, Finland (T.H.); Toxicology and Safety Assessment, Kabi Pharmacia AB, Helsingborg, Sweden (N.G.I.); the Division of Clinical Virology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden (A.E.); and the Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Huddinge Hospital, Huddinge, Sweden (G.E.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Ehrnst","sequence":"additional","affiliation":[{"name":"the Department of Infectious Diseases, University Hospital, Uppsala, Sweden (J.F., K.P., N.G.I., G.F.); the Department of Virology, University of Turku, Finland (T.H.); Toxicology and Safety Assessment, Kabi Pharmacia AB, Helsingborg, Sweden (N.G.I.); the Division of Clinical Virology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden (A.E.); and the Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Huddinge Hospital, Huddinge, Sweden (G.E.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.G.","family":"Ilba\u00a8ck","sequence":"additional","affiliation":[{"name":"the Department of Infectious Diseases, University Hospital, Uppsala, Sweden (J.F., K.P., N.G.I., G.F.); the Department of Virology, University of Turku, Finland (T.H.); Toxicology and Safety Assessment, Kabi Pharmacia AB, Helsingborg, Sweden (N.G.I.); the Division of Clinical Virology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden (A.E.); and the Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Huddinge Hospital, Huddinge, Sweden (G.E.)."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Friman","sequence":"additional","affiliation":[{"name":"the Department of Infectious Diseases, University Hospital, Uppsala, Sweden (J.F., K.P., N.G.I., G.F.); the Department of Virology, University of Turku, Finland (T.H.); Toxicology and Safety Assessment, Kabi Pharmacia AB, Helsingborg, Sweden (N.G.I.); the Division of Clinical Virology, Huddinge University Hospital, Karolinska Institute, Huddinge, Sweden (A.E.); and the Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Huddinge Hospital, Huddinge, Sweden (G.E.)."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_2_1_2","first-page":"424","volume":"101","year":"1980","unstructured":"Woodruff JF. Viral myocarditis: a review. Am J Pathol. 1980;101:424-479.","journal-title":"Am J Pathol"},{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1699-0463.1990.tb01071.x"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(90)90098-7"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb15763.x"},{"key":"e_1_3_2_5_2","unstructured":"Grist NR Reid D. Epidemiology of viral infections of the heart. In: Banatvala JE ed. Viral Infections of the Heart. London UK: Edward Arnold; 1993:23-31."},{"key":"e_1_3_2_6_2","first-page":"163","volume":"18","year":"1987","unstructured":"McManus BM, Gauntt CJ, Cassling RS. Immunopathologic basis of myocardial injury. Cardiovasc Clin.. 1987;18:163-184.","journal-title":"Cardiovasc Clin."},{"key":"e_1_3_2_7_2","unstructured":"Gauntt C Higdon A Bowers D Maull E Wood J Crawley R. What lessons can be learned from animal model studies in viral heart disease? Scand J Infect Dis Suppl. 1993;suppl 88:49-65."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","unstructured":"Friman G Wessle\u00b4n L Fohlman J Karjalainen J Rolf C. The epidemiology of infectious myocarditis lymphocytic myocarditis dilated cardiomyopathy and myocarditis-associated sudden unexpected death. Eur Heart J. 1995; In press.","DOI":"10.1093\/eurheartj\/16.suppl_O.36"},{"key":"e_1_3_2_9_2","unstructured":"Maisch B Herzum M Scho\u00a8nian U. Immunomodulating factors and immunosuppressive drugs in the therapy of myocarditis. Scand J Infect Dis Suppl. 1993;suppl 88:149-162."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0166-3542(88)90021-6"},{"key":"e_1_3_2_11_2","first-page":"257","volume":"2","year":"1989","unstructured":"Ilba\u00a8ck NG, Fohlman J, Friman G. The protective effect of selenium on the development of coxsackievirus B3 induced inflammatory lesions in the murine myocardium. J Trace Elem Exp Med. 1989;2:257-266.","journal-title":"J Trace Elem Exp Med"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.137.5.1695"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.6.883"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.1.30"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/154.4.676"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.63.5.2002-2007.1989"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.10.3304"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(87)90075-4"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.12.2069"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.4049\/jimmunol.134.6.3956","volume":"134","year":"1985","unstructured":"Kalland T, Alm G, Sta\u02dalhandske T. Augmentation of mouse natural killer cell activity by LS 2616, a new immunomodulator. J Immunol. 1985;134:3956-3961.","journal-title":"J Immunol"},{"key":"e_1_3_2_21_2","unstructured":"Grandien M Forsgren M Ehrnst A. Enteroviruses and reoviruses. In: Schmidt NJ Emmons RW eds. Diagnostic Procedures for Viral Rickettsial and Chlamydial Infections. 6th ed. Washington DC: American Public Health Association; 1989:513-578."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1980.tb06030.x"},{"key":"e_1_3_2_23_2","unstructured":"Sambrook J Fritsch EF Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor NY: Cold Spring Harbor Laboratory Press; 1989."},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)75947-X"},{"key":"e_1_3_2_25_2","first-page":"14693","volume":"258","year":"1985","unstructured":"Sackstein R, Colten HR, Goldberger G, Edge MD, Tack BF, Cohen AS, Whitehead AS. Phylogenetic conservation of a class III major histocompatibility complex antigen, factor B isolation and nucleotide sequencing of mouse factor B cDNA clones. J Biol Chem. 1985;258:14693-14697.","journal-title":"J Biol Chem"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.3.708"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/13.7.2485"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.34.6.575"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb15763.x"},{"key":"e_1_3_2_30_2","unstructured":"Wessle\u00b4n L Waldenstro\u00a8m A Lindblom L H\u00f8yer S Friman G Fohlman J. Genotypic and serotypic profile in dilated cardiomyopathy. Scand J Infect Dis Suppl. 1993;suppl 88:87-91."},{"key":"e_1_3_2_31_2","unstructured":"Klingel K Kandolf R. The role of enterovirus replication in the development of acute and chronic heart muscle disease in different immunocompetent mouse strains. Scand J Infect Dis Suppl. 1993;suppl 88:79-85."},{"key":"e_1_3_2_32_2","unstructured":"Archard LC Khan M Why HJF Richardson PJ. Nucleotide sequencing of PCR-amplified sequences from endomyocardial biopsies: identification of the Coxsackie B virus serotypes associated with myocarditis and dilated cardiomyopathy. International Symposium on Cardiomyopathies Pathogenetic Mechanisms and Clinical Aspects. Warsaw Poland; September 30-October 1 1993."},{"key":"e_1_3_2_33_2","first-page":"141","volume":"35","year":"1993","unstructured":"Kandolf R, Klingel K, Zell R, Selinka H-C, Raab U, Schneider-Brachert W, Bu\u00a8ltmann B. Molecular pathogenesis of enterovirus-induced myocarditis: virus persistence and chronic inflammation. Intervirology. 1993;35:141-151.","journal-title":"Intervirology"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.5.866"},{"key":"e_1_3_2_35_2","unstructured":"Pauksen K Ilba\u00a8ck NG Friman G Fohlman J. Therapy of coxsackie virus B3 induced myocarditis with WIN 54 954 in different formulations. Scand J Infect Dis Suppl. 1993;suppl 88:125-130."},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/0882-4010(88)90027-7"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(88)92618-6"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.12.4.498"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112099"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)95732-7"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112721"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.162.3.930"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3010455"},{"key":"e_1_3_2_44_2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.4049\/jimmunol.138.3.856","volume":"138","year":"1987","unstructured":"Falus A, Beuscher HU, Auerbach HS, Colten HR. Constitutive and IL 1-regulated murine complement gene expression is strain and tissue specific. J Immunol. 1987;138:856-860.","journal-title":"J Immunol"},{"key":"e_1_3_2_45_2","unstructured":"Ilba\u00a8ck NG Wessle\u00b4n L Pauksen K Sta\u02dalhandske T Friman G Fohlman J. Effects of the antiviral WIN 54 954 and the immune modulator LS 2616 on cachectin\/TNF and gamma-interferon responses during viral heart disease. Scand J Infect Dis Suppl. 1993;suppl 88:117-123."},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.4.522"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/01.CIR.94.9.2254","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T15:32:58Z","timestamp":1715527978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/01.CIR.94.9.2254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,11]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[1996,11]]}},"alternative-id":["10.1161\/01.CIR.94.9.2254"],"URL":"https:\/\/doi.org\/10.1161\/01.cir.94.9.2254","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"type":"print","value":"0009-7322"},{"type":"electronic","value":"1524-4539"}],"subject":[],"published":{"date-parts":[[1996,11]]},"assertion":[{"value":"1995-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-06-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"1996-11-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}